Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). METHODS: In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 patients are reported here (part 1). The primary end points for part 1 were the resolution of steatohepatitis without worsening of liver fibrosis and reduction in liver fibrosis without worsening of steatohepatitis. RESULTS: Resolution of steatohepatitis without worsening of fibrosis occurred in 62.9% of the 534 patients in the semaglutide group and in 34.3% of the 266 patients in the placebo group (estimated difference, 28.7 percentage points; 95% confidence interval [CI], 21.1 to 36.2; P<0.001). A reduction in liver fibrosis without worsening of steatohepatitis was reported in 36.8% of the patients in the semaglutide group and in 22.4% of those in the placebo group (estimated difference, 14.4 percentage points; 95% CI, 7.5 to 21.3; P<0.001). Results for the three secondary outcomes that were included in the plan to adjust for multiple testing were as follows: combined resolution of steatohepatitis and reduction in liver fibrosis was reported in 32.7% of the patients in the semaglutide group and in 16.1% of those in the placebo group (estimated difference, 16.5 percentage points; 95% CI, 10.2 to 22.8; P<0.001). The mean change in body weight was -10.5% with semaglutide and -2.0% with placebo (estimated difference, -8.5 percentage points; 95% CI, -9.6 to -7.4; P<0.001). Mean changes in bodily pain scores did not differ significantly between the two groups. Gastrointestinal adverse events were more common in the semaglutide group. CONCLUSIONS: In patients with MASH and moderate or advanced liver fibrosis, once-weekly semaglutide at a dose of 2.4 mg improved liver histologic results. (Funded by Novo Nordisk; ClinicalTrials.gov number, NCT04822181.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A recent study reported significant effects on the resolution of MASLD without worsening of fibrosis, but also significant improvements in fibrosis without worsening of MASLD after 72 weeks of treatment with semaglutide.84”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [84]
In the citing paper
“Part 1 of a phase III trial investigating semaglutide for the treatment of MASH demonstrated resolution of steatohepatitis with no worsening of fibrosis in 63% of the semaglutide group, compared with 34% in the placebo group (68).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“In addition, 37% of the semaglutide group showed improvement in fibrosis without worsening of steatohepatitis, compared with 23% in the placebo group.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [68]
In the citing paper
“As for resmitirom, semaglutide is indicated for MASH patients with moderate to advanced liver fibrosis, but not liver cirrhosis (53).”
From Targeting macrophages in liver fibrosis (2026) · cites this paper as [53]
In the citing paper
“In the ESSENCE phase 3 trial, semaglutide showed a significant antifibrotic effect in patients with MASH and stage F2–F3 fibrosis (225).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [225]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationRinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationA phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 201–300 of 1,000
Current treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 8
Nutrition in MASLD: a patient focused, evidence-based clinician’s guide
Pekarska, K., Brennan, P. N., Wajcman, D. I., Towey, J., Cox, L., Weatherby, K., McPherson, S., Stine, J., Willemse, J., Li, W., et al. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2025-103183 · Cited by 8
“There are a few pharmacological treatments that show promise in managing patients with MASLD; however, 15–17 the first-line evidence-based intervention remains lifestyle change.”
Siranart, N., Thompson, C. C., & Jirapinyo, P. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000871 · Cited by 8
“S an y a l e t a l [ 6 ] S e m ag l u t i de was 5% (95% CI: 2%–9%, I 2 = 63.7”
InfluentialAl-Dahi, W. A., Alenezi, A., Alessa, T., Alhamdan, R., Al-Humood, K., Alqallaf, A., AlOtaibi, T. M., AlRajab, H., Alshammari, A. M., Alyousef, A., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-025-01838-0 · Cited by 9
Monami, M., Belluzzi, A., Buscemi, S., Busetto, L., Cohen, R., Luca, M. D., Galli, A., Mannucci, E., Petry, T. B. Z., Ragghianti, B., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70617 · Cited by 10
Tsakiridis, E. E., & Steinberg, G. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70624 · Cited by 10
MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues
Ha, S., Zhang, X., Lan-juan, L., & Yu, J. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.04.048 · Cited by 8
MASLD, diabetes and PMOS across the female life stages
Stener‐Victorin, E., Carlsson, S., Hagström, H., & Taebnia, N. (2026) · Diabetologia · doi:10.1007/s00125-026-06761-y · Cited by 7
Alcohol-Related Liver Disease: A Review
Krag, A. A., Åberg, F., Mellinger, J. L., Lee, B. P., & Israelsen, M. E. (2026) · JAMA · doi:10.1001/jama.2026.12038 · Cited by 9
Loomba, R. S., George, J., Castéra, L., Francque, S., Lawitz, E., Shoeb, A., Clausen, J. O., Andersen, B., Larsen, A. B., & Gluud, L. L. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00123-8 · Cited by 9
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Boutari, C., Hill, M. A., & Mantzoros, C. S. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156397 · Cited by 7
Drexel, H., Festa, A., Schmidt, T. A., Rocca, B., Dobrev, D., Agewall, S., Tamargo, J. L., & Kaser, S. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf076 · Cited by 7
Chemoprevention of hepatocellular carcinoma
Schwenk, S., & Kaplan, D. E. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000836 · Cited by 7
“[111,112] Given compelling evidence that GLP1RA therapy can reverse hepatic steatosis and slow the progression of hepatic fibrosis, both key risk factors for hepatocarcinogenesis, the role of GLP1RA in the prevention of HCC development is of growing interest.”
Choi, J. H., Kang, S., Kim, S., Kim, W. J., Kim, J. M., Bae, J., Yun, J., Jeon, E. J., Kim, Y., Bae, J. H., et al. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0978 · Cited by 9
Resmetirom and beyond: A new era in MASLD therapeutics
Johnson-Moore, T., Simmons, D., Okafor, A. C., Washington, D., & Baskaran, P. (2025) · Liver Research · doi:10.1016/j.livres.2025.10.004 · Cited by 6
Review Article: The Evolving Role of GLP ‐1 Receptor Agonists in Gastroenterology Practice
Pomenti, S. F., Gerber, A. R., Katzka, D. A., Camilleri, M., & Hur, C. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70450 · Cited by 9
Kan, R., Wang, S., Meng, X., Guo, Y., Li, D., & Yu, X. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01995-z · Cited by 7
Panuganti, V. K., Alluri, C. V., Mohammad, J., Dundigalla, M. R., Madala, P. K., KSSVV, S., & shaik, A. H. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i12.113658 · Cited by 6
Ghodrati, F., Zhang, A. B., & Mahmud, N. (2026) · Gastroenterology report · doi:10.1093/gastro/goag006 · Cited by 6
Metabolic Dysfunction-Associated Steatotic Liver Disease and Sarcopenia: Review of Literature
Nishikawa, H., Kim, S. K., Yoshio, S., & ASAI, A. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041661 · Cited by 7
“This study reported an average weight loss of 10.5% in the semaglutide group [111].”
InfluentialBrouwer, W. P., Vonghia, L., Thiele, M. S., Schattenberg, J. M., Anastasiou, F., Beckmann, S., Bugianesi, E., Castéra, L., Caussy, C., Cordie, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101798 · Cited by 12
“Phase III data for semaglutide 2.4 mg in non-cirrhotic MASH 145 led to accelerated FDA approval, and with several drugs in the pipeline, it is likely that the armamentarium of liver-directed MASH therapies will substantially expand soon.”
InfluentialSelf-citationJirapinyo, P., Papke, D. J., García–Tsao, G., Ryou, M. K., Zhao, L., Zucker, S. D., & Thompson, C. C. (2026) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2026.02.042 · Cited by 6
Bril, F. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70553 · Cited by 7
GLP-1RA plus SGLT2i combination therapy and liver fibrosis progression in MASLD with type 2 diabetes
Choi, J., Mitchell, G., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000949 · Cited by 6
“[5] Similarly, another randomized trial reported that sodium-glucose cotransporter-2 inhibitor (SGLT2i) improved steatosis and fibrosis indices in patients with MASLD, highlighting their potential as effective hepatoprotective agents.”
Ho, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 7
EASL position paper on preclinical models of steatotic liver disease
Gallage, S., Castro, R. E., Estall, J. L., Tabas, I. A., Anstee, Q. M., TINIAKOS, D. G., Szabó, G., Yu, J., Desdouets, C., Tacke, F., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.04.029 · Cited by 8
Gál, A. R., Szokodi, I., Vizvári, Z., Győrfi, N., Vereczkei, A. G., Petykó, Z., Karádi, Z., & Tóth, A. (2026) · Antioxidants · doi:10.3390/antiox15060710 · Cited by 6
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 7
Crespo, J., Iruzubieta, P., & Fernández‐Rodríguez, C. (2025) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2025.11339/2025 · Cited by 11
Papadakos, S. P., Georgiadou, C., Kassi, E. N., Velliou, R.-I., & Chatzigeorgiou, A. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2579124 · Cited by 6
Roeb, E., Canbay, A. E., Bantel, H., Geier, A., Hofmann, W. P., Roden, M., Schattenberg, J. M., Stefan, N., Tacke, F., für die Autoren des DGVS Leitlinienkomitees/for the authors of the DGVS guideline committee, et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2397 · Cited by 6
Self-citationMoreno, Ó., Reyes‐García, R., Guillen-Morote, C., Doulatram‐Gamgaram, V. K., Cases, C. C., Mendoza, N. A., Pérez, C. T., Cárdenas‐Salas, J., Martínez‐Fuster, S., Lardiés‐Sánchez, B., et al. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf227 · Cited by 8
Saidi, A. N., Konings, L. A. M., Dietvorst, C. A. W., de Jong, V., Brouwer, W. P., van der Lelij, A., Alings, M., van Wenum, M., Rauh, S. P., Xu, W., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70071 · Cited by 6
“19 Similarly, a recent study comparing lira-glutide to matched lifestyle-induced weight loss in non-diabetic MASLD patients found that comparable weight reductions yielded similar improvements in hepatic steatosis and disease activity, highlighting weight loss as the primary mediator of liver…”
Kumar, A. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.1058 · Cited by 7
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2566258 · Cited by 6
“Recently, sema-glutide was shown to improve fibrosis in patients with MASH [13], and its approval for the treatment of MASH followed that of resmetirom.”
Barazzoni, R., Monami, M., Buscemi, S., Busetto, L., Luca, M. D., Navarra, G., Ragghianti, B., Silverii, G. A., Belluzzi, A., Mannucci, E., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70204 · Cited by 7
Quantitative Approaches to Accelerate MASH Drug Discovery and Development
Abouelhassan, Y., Tallapaka, S. B., Mehrani, R., Siler, S. Q., Li, Q., Wang, Z., & Trujillo, M. E. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70103 · Cited by 5
Overeating: A Conundrum of Lipid Metabolism and Inflammation in Obesity and Cancer
Surumbayeva, A., Saiman, Y., & Astsaturov, I. A. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70104 · Cited by 6
Dadey, E., Lim, T., & Makaronidis, J. (2025) · Clinical Medicine · doi:10.1016/j.clinme.2025.100528 · Cited by 5
“21 , 22 The ESSENCE trial (2025) showed an improvement in fibrosis in 36.8% of patients taking weekly semaglutide injections (mostly with T2D) vs 22.4% on placebo.”
InfluentialLi, D., & Zhang, X. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000846 · Cited by 10
“[ 175 ] Mechanically, recent data suggested that Semaglutide promoted the transition of circulating proteomic pattern from MASH to healthy individuals, in addition to its well-known effects on weight loss.”
Screening and management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Geary, A. (2025) · JAAPA · doi:10.1097/01.jaa.0000000000000296 · Cited by 5
Park, S.-H., Ma, G., Park, S. J., Yang, S.-B., Seo, M., Lee, J.-H., Kweon, S., & Park, J. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123903 · Cited by 7
Pediatric MASLD in Severe Obesity: Current Clinical Perspectives on Diagnosis and Treatment
Kostrzeba, E., Bik-Multanowski, M., Brandt, S., Małecka‐Tendera, E., Mazur, A., Ranke, M. B., Wabitsch, M., Wójcik, M., Zachurzok, A., & Petriczko, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010137 · Cited by 7
“However, dedicated pediatric trials and long-term safety data are essential before such treatments can be recommended in children [68].”
Immunological mechanisms underlying fibrotic diseases via single-cell technologies
Koda, Y., Nakamoto, N., & Kanai, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1720047 · Cited by 6
Convergent Metabolic Pathways in MASH Therapeutics: An AMPK ‐Centric Analysis
Choi, S., Jung, J., Seo, Y., Song, S., Ham, J., Chung, H., Ramadan, Y., & Choi, K. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71023 · Cited by 6
“Semaglutide has demonstrated efficacy in resolving steatohepatitis in a considerable percentage of patients [11].”
InfluentialPοlyzos, S. A., Kountouras, J., Duntas, L. H., & Targher, G. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70507 · Cited by 7
“3,5 Although it is rational that their concomitant administration might have an additive effect on gastrointestinal adverse events, this remains largely unproven.”
Yang, J., Hwang, Y., Ju, J., Han, S., An, J., & Shim, J. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001695 · Cited by 8
Llach, J., Sòria, A., Graupera, I., & Cardenas, A. (2026) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2026.2632873 · Cited by 5
“Figure 1 It is noteworthy that, over the last 2 years, two pharmacological agents have received the FDA approval for the treat-ment of patients with MASLD without cirrhosis (fibrosis stages F2 and F3) [27,36].”
Fakhoury, B., de León, I. H.-D., Patel, K. S., Díaz, L. A., & Arab, J. P. (2026) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70259 · Cited by 10
Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review
Papapetropoulos, A., Topouzis, S., Alexander, S. P. H., Cortese-Krott, M. M., Helyes, Z., Martemyanov, K. A., Mauro, C., Nagercoil, N., Panettieri, R., Patel, H. H., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70376 · Cited by 5
Lian, J., Lareu, R. R., Patil, M., & Falasca, M. (2026) · Liver International · doi:10.1111/liv.70576 · Cited by 6
“More recently, Wegovy (semaglutide), a glucagone-like peptide-1 (GLP-1) agonist, also achieved regulatory approval in this therapeutic domain (NCT04822181) [13].”
Athinarayanan, S. J., Wolfberg, A., Shanmugam, P., Hameed, B., & Bonacini, M. (2026) · Hepatology · doi:10.1097/hep.0000000000001713 · Cited by 5
Alamgir, M., Sohal, A., & Kowdley, K. V. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s560039 · Cited by 6
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Gee, M. F. W., Fonstad, R. K., Vol, E. B. D., Brown, C., Feld, J. J., Patel, K., & Sanyal, A. J. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000931 · Cited by 6
“[4,10,20] Further, in large phase 3 clinical trials of patients with F2–F3 MASH, baseline ELF values below one standard deviation of the mean were near to 9.00, [38,39] providing supporting evidence for this threshold to detect most patients with F2 fibrosis or higher.”
InfluentialSelf-citationAkuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Hepatology Research · doi:10.1111/hepr.70188 · Cited by 8
“Semaglutide, evaluated in the ESSENCE trial (2025), achieved MASH resolution in 63% of patients and fibrosis improvement in 37% [84, 85].”
Albusta, N., Isa, S., & Alrahma, H. N. S. (2026) · Diseases · doi:10.3390/diseases14050173 · Cited by 8
“Semaglutide, a glucagon-like peptide-1 receptor agonist, received accelerated FDA approval in August 2025 for adults with noncirrhotic MASH with moderate to advanced fibrosis, to be used with diet and exercise [16,17].”
InfluentialInterventions for the prevention and management of cardiometabolic multiple long-term conditions
Valabhji, J., Hope, D. C. D., SAYED, N. A. E., Godia, P., Lawson, C. A., Seidu, S., & Khunti, K. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00608-2 · Cited by 6
Fomin, M., Zapf, K., Schieffer, E., Freitag, J., Bange, G., & Schieffer, B. (2026) · Inflammation Research · doi:10.1007/s00011-026-02283-w · Cited by 6
Hu, Y., Lin, C., Zhang, L., Jiang, X., Li, H., & Wu, Y. (2026) · Advanced Science · doi:10.1002/advs.202523582 · Cited by 8
“Semaglu-tide, a GLP-1 receptor agonist, has demonstrated significant efficacy in MASH clinical trials [ 240, 241 ].”
Late-life semaglutide treatment slows ageing and extends lifespan in female mice
Feng, Y., Barthez, M., Wang, Y., Chen, Y., Qiu, H., Wang, C.-L., Heydari, K., Delcroix, M., Rasmussen, L. J., Bohr, V. A., et al. (2026) · Nature · doi:10.1038/s41586-026-10940-7 · Cited by 7
Mabuda, T. I., Sibuyi, N. R. S., Fadaka, A. O., Meyer, M., Madiehe, A. M., & Gabuza, K. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09980-7 · Cited by 6
Sebastiani, G., Raggi, P., & Guaraldi, G. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.06.075 · Cited by 8
Kim, J. W., Raggi, P., Carreau, A., Wharton, S., CHENG, A. Y. Y., & Swain, M. G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70117 · Cited by 6
Jensterle, M., & Janež, A. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2554668 · Cited by 5
“…risk of major cardiovascular events in patients with obesity and cardiovascular disease and a reversal of steatohepatitis with lowering of liver fibrosis in patients with metabolic dysfunction – associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis [5–7].”
Personalized management of metabolic dysfunction-associated steatotic liver disease
Sun, Z., Chan, K. M., & Jin, H. (2025) · iLiver · doi:10.1016/j.iliver.2025.100207 · Cited by 5
“4 While substantial progress has been made in treating MASLD, options for non-MASH patients, who represent the majority, remain limited.”
Cardiovascular and hepatic outcomes: prognostic differences across MASLD-MetALD-ALD continuum
Lee, H. A., Kim, G., & Kim, W. (2026) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2026.0367 · Cited by 7
Kumar, S., Lahooti, A., Hajifathalian, K., Critelli, B., Hassan, A., Johnson, K. E., Baig, M. R., Akagbosu, C., Canakis, A., Hassan, K., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09218-1 · Cited by 4
“…part one of the ESSENCE trial showed that semaglutide significantly improved liver fibrosis without worsening steatohepatitis and achieved steatohepatitis resolution without exacerbating fibrosis compared to placebo, reinforcing its potential role in treating these patients in the future [17, 18].”
Palmer, M., Arman, A. C., Lawitz, E., Sanchez, W. E., Mittal, S., Hassanein, T., Hansen, S. G., Meidling, J., Cunningham, B., Buss, N., et al. (2025) · Liver international communications. · doi:10.1002/lci2.70028 · Cited by 4
Elangovan, H., Loomba, R. S., Muthiah, M. D., Schattenberg, J. M., Zheng, M., Noureddin, M., Mantzoros, C. S., & George, J. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0857 · Cited by 5
Hughes, J. W., Levin, J. B., Sajatovic, M., & Sclair, S. N. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000860 · Cited by 6
“[1] Following the positive results of the Phase 3 ESSENCE trial, [2] on August 15, 2025, the FDA-approved Wegovy (semaglutide) for the treatment of metabolic dysfunction – associated steatohepatitis (MASH).”
InfluentialCar, M., Erceg, D., Udovičić, M., Bokun, T., & Rahelić, D. (2025) · Medicina · doi:10.3390/medicina61122210 · Cited by 4
“…real-time monitoring to guide pricing and reimbursement policy, especially considering these drugs are emerging as a promising option for the obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) with fibrosis, which might substantially consume the healthcare budget [18–21].”
Xu, Z., Zhu, Y., Chen, F., Fan, Q.-Y., Wang, R., Fu, Y., Wu, X., Zhu, L., Ha, F., Ye, Q., et al. (2025) · Liver International · doi:10.1111/liv.70491 · Cited by 7
Ali, B., Samuel, R. E., Kramer, J. R., Li, L., Yu, X., Cao, Y., Desiderio, R., Cholankeril, G. T., Asch, S. M., El‐Serag, H. B., et al. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000878 · Cited by 4
“[7,8] Measuring the burden of cirrhosis and its complications in MASLD is crucial, as these data can provide a critical insight into the magnitude of the problem and inform changes in the pattern of care delivery to patients with MASLD.”
MASLD as a complication of obesity must include liver risk stratification
Rinella, M. E., Sanyal, A. J., Loomba, R. S., Noureddin, M., Bansal, M. B., Newsome, P. N., & Ratziu, V. (2026) · Nature Medicine · doi:10.1038/s41591-025-04130-7 · Cited by 4
Self-citationShao, X., You, J., Zhang, H., & Jiang, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1659740 · Cited by 4
Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Trivedi, K., & Dolinsky, V. W. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0163 · Cited by 7
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
“The ESSENCE trial [93] enrolled adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced fibrosis (stage 2-3).”
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Musso, G., Pinach, S., Cassader, M., Mariano, F., & Gambino, R. (2026) · Med · doi:10.1016/j.medj.2025.100959 · Cited by 4
Reconstructing Liver Fibrosis: 3D Human Models, Microbiome Interfaces, and Therapeutic Innovation
Nair, D. G., Nair, D. B., & Weiskirchen, R. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48020165 · Cited by 4
“Multicellular spheroids and organoids are effective for examining early hepatocyte injury, HSC activation, and the onset of extracellular matrix deposition under defined metabolic or inflammatory cues, consistent with reports showing their utility in capturing early fibrogenic transitions [3].”
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Farrell, A., Paris, T., Parr, E. B., George, E. S., Howell, J. A., Croagh, C. M. N., Sutherland, T., Page, M., McKelvie, P. A., Thompson, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101787 · Cited by 6
“20 Our study did not detect a change in fibrosis; however, it was not powered to do so, and the follow-up interval was not optimised to capture this outcome.”
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Hwang, S. Y., Hsieh, P., Díaz, L. A., Goodman, R. P., Schaefer, E. A. K., Wong, R. J., Luther, J., & Zhang, W. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003162 · Cited by 4
Thermoacoustic Ultrasound Assessment of Liver Steatosis—A Novel Approach for MASLD Diagnosis
Cho, J. H., Bull, C. M., Thornton, M. M., Gao, J. S., Rubin, J. M., & Steinberg, I. (2026) · Diagnostics · doi:10.3390/diagnostics16050804 · Cited by 4
“These agents exhibit high rates of MASH resolution and marked improvements in hepatic fibrosis, firmly establishing them as a cornerstone of future metabolic-based therapeutic strategies [28].”
Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives
Fu, L., Ding, R., Xu, G., Hu, J., & Yang, P. C. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156594 · Cited by 6
Njei, B. M., Al‐Ajlouni, Y. A., Tanih, D. N., Kanmounye, U. S., Boateng, S., Halwani, K. W., Nguefang, G., & Lim, J. K. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-026-00741-0 · Cited by 4
“The phase III ESSENCE trial assessed semaglutide in patients with non-cirrhotic MASH and metabolic risk factors, reporting high rates of steatohepatitis resolution and clinically meaningful improvements in fibrosis over a 72-week histologic assessment period [11].”
Lindstad, T. M., Pourteymour, S., Lee-Ødegård, S., Drevon, C. A., & Norheim, F. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27072941 · Cited by 5
Issachar, A., Razi, T., Borochov, I., Duskin‐Bitan, H., & Arbel, R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70763 · Cited by 4
Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan
Seko, Y., & Yamaguchi, K. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02401-9 · Cited by 4
Richard, K. S. E., Rohilla, S., Gade, R., Arias, F., & Rom, O. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01425-z · Cited by 4
“Those benefits extend further, as semaglutide has now been approved for the treatment of MASH [119 ].”
Muscogiuri, G., Albertelli, M., Arnaldi, G., Barrea, L., Bellastella, G., Bonomi, M., Caputo, M., Caprio, M., Cignarelli, A., Gioia, L. D., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02862-y · Cited by 4
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Dinkov, B. (2026) · Biomedicines · doi:10.3390/biomedicines14061235 · Cited by 4
Henriques, J. P., Weckwerth, A. V. B., Sant’Ana, A. C. P., Damante, C. A., Santos, C. F., & Negrato, C. A. (2026) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2026.06.008 · Cited by 5
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Metadata
- Authors
- Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., & Ratziu, V.
- Affiliations
- Virginia Commonwealth University (US)
- King's College London (GB)
- Novo Nordisk (Denmark) (DK)
- University of Turin (IT)
- University of Chicago (US)
- Düsseldorf University Hospital (DE)
- Inserm (FR)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-06-05
- Volume
- 392
- Issue
- 21
- Pages
- 2089-2099
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4409963211
- Cited by
- 1,115
- References
- 39
- Citations by year
- 2026: 813 · 2025: 302
- FWCI
- 767.51
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Scopus (Elsevier) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, nonalcoholic steatohepatitis, GLP-1 receptor agonists, liver fibrosis, weight loss, body mass index, non-alcoholic fatty liver disease, fibrosis regression, interim analysis, multiple testing correction, non-invasive fibrosis markers
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Adult, Aged, Biopsy, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Treatment Outcome, Glucagon-Like Peptide 1, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.